Werewolf Therapeutics, Inc.
HOWL Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.98
KIRA · Stoqly’s AI analyst, in plain words
- Werewolf Therapeutics, Inc. lost $60.8M in fiscal 2025.
- Free cash flow was −$60.3M in fiscal 2025, — of revenue.
- Werewolf Therapeutics, Inc. has $25.0M more cash than debt.
Market cap
$47.6M
P/E
—
Revenue
—
Net income
−$60.8M
Free cash flow
−$60.3M
Operating margin
—
Werewolf Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$60.8M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Werewolf Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- Werewolf Therapeutics, Inc.
- CIK
- 0001785530
Werewolf Therapeutics, Inc. · HOWL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$50.0M | −$53.8M | −$37.4M | −$70.5M | −$60.8M |
| Diluted EPS | −$10.94 | −$1.86 | −$1.05 | −$1.63 | −$1.33 |
| Cash | |||||
| Cash from operations | −$42.9M | −$40.6M | −$32.6M | −$56.2M | −$60.3M |
| Capital expenditure | $0.5M | $3.6M | $0.8M | $0.3M | $0.0M |
| Free cash flow | −$43.4M | −$44.2M | −$33.4M | −$56.4M | −$60.3M |
| Share count change | 1,736.3% | 56.4% | 23.5% | 23.0% | 6.7% |
| Debt and strength | |||||
| Cash and short-term investments | $158M | $129M | $134M | $111M | $57.1M |
| Debt incl. finance leases | — | — | $40.0M | $32.1M | $32.1M |
| Shareholders' equity | $153M | $122M | $111M | $73.4M | $24.8M |
| Current ratio | 13.6x | 5.8x | 7.1x | 7.4x | 1.6x |
| Interest coverage | — | — | −12.9x | −15.8x | −11.5x |
| Returns and quality | |||||
| Return on capital | — | — | −187.9% | — | — |
| Return on equity | −99.1% | −39.1% | −32.0% | −76.3% | −123.9% |
| Return on tangible equity | −132.2% | −44.0% | −33.6% | −96.1% | −245.2% |
| Piotroski F-score | — | — | — | 2 | 1 |
| Altman Z'' | 5.0 | −0.4 | −1.7 | −8.0 | −25.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$6.4M
10 insiders
Of sales under plans
85%
$5.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Werewolf Therapeutics, Inc. · HOWL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.98 a share, the company is worth $47.6M.
Source: SEC EDGAR XBRL filings (CIK 0001785530). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.